Today's Perilous Reversal Stock: ZIOPHARM Oncology (ZIOP)
Trade-Ideas LLC identified
(
) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified ZIOPHARM Oncology as such a stock due to the following factors:
- ZIOP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $26.2 million.
- ZIOP has traded 64,980 shares today.
- ZIOP is down 4.7% today.
- ZIOP was up 7.6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ZIOP with the Ticky from Trade-Ideas. See the FREE profile for ZIOP NOW at Trade-Ideas
More details on ZIOP:
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Currently there is 1 analyst that rates ZIOPHARM Oncology a buy, no analysts rate it a sell, and 3 rate it a hold.
The average volume for ZIOPHARM Oncology has been 3.2 million shares per day over the past 30 days. ZIOPHARM Oncology has a market cap of $1.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.26 and a short float of 32.3% with 15.44 days to cover. Shares are up 105.9% year-to-date as of the close of trading on Wednesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates ZIOPHARM Oncology as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.
Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 154.9% when compared to the same quarter one year ago, falling from -$5.58 million to -$14.21 million.
- Net operating cash flow has significantly decreased to -$11.69 million or 53.16% when compared to the same quarter last year. Despite a decrease in cash flow ZIOPHARM ONCOLOGY INC is still fairing well by exceeding its industry average cash flow growth rate of -79.03%.
- ZIOPHARM ONCOLOGY INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, ZIOPHARM ONCOLOGY INC continued to lose money by earning -$0.32 versus -$0.66 in the prior year. For the next year, the market is expecting a contraction of 46.9% in earnings (-$0.47 versus -$0.32).
- Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Biotechnology industry and the overall market, ZIOPHARM ONCOLOGY INC's return on equity significantly trails that of both the industry average and the S&P 500.
- ZIOP has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 9.05, which clearly demonstrates the ability to cover short-term cash needs.
- You can view the full ZIOPHARM Oncology Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.